Centanafadine
As of the edition of 20 October 2026, Centanafadine is a small molecule: marketed, first approved in 2026 (US); acts on SLC6A2, SLC6A3 and SLC6A4; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Simtriyo
- First approved
- 24 July 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Otsuka
- Registered trials
- 26, 1 stopped early
- Disease areas
- Mental health; Chemically induced
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 7 | 0 | 1 |
| Phase 2 | 6 | 6 | 0 | 0 |
| Phase 3 | 12 | 7 | 5 | 0 |
| All trials | 26 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Otsuka | Lead sponsor of trials | 2013 to now |